Læknaneminn - 01.04.2020, Qupperneq 31

R
it
rý
n
t
e
fn
i
R
itr
ýn
t e
fn
i
3
1
Heimildir
1. Fernández de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia:
consensus statement on diagnostic requirements, response criteria and
treatment recommendations by the International Myeloma Working
Group. Leukemia 2012;27(4):780-91.
2. Nahi H, Genell A, Wålinder G, et al. Incidence, characteristics, and
outcome of solitary plasmacytoma and plasma cell leukemia. Population-
based data from the Swedish Myeloma Register. Eur J Haematol.
2017;99(3):216–222
3. Ramsingh G, MehanP, Luo J et al. Primary plasma cell leukemia. Cancer
2009; 115:5734-5739.
4. Ravi P, Kumar SK, Roeker L et al. Revised diagnostic criteria for
plasma cell leukemia: results of a Mayo Clinic study with comparison of
outcomes to multiple myeloma. Blood Cancer Journal 2018; 8(12):116.
5. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic
malignancies in Europe by morphologic subtype: results of the
HAEMACARE project. Blood 2010; 116(19):3724-3734.
6. Tiedemann RE, Gonzalez-Paz N, Santana-Davila R, et al. Genetic
aberrations and survival in plasma cell leukemia. Leukemia 2008;
22(5):1044-1052.
7. Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma,
and plasma cell leukemia. Hematology/Oncology Clinics of North
America 1999;13:1259–1272.
8. Nahi H, Genell A, Wålinder G, et al. Incidence, characteristics, and
outcome of solitary plasmacytoma and plasma cell leukemia. Population-
based data from the Swedish Myeloma Register. Eur J Haematol.
2017;99(3):216–222.

9. Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients
with primary plasma cell leukemia: a population-based analysis. Blood
2014; 124(6):907–912
10. Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell
leukemia: a retrospective multicenter study of 73 patients. Annals of
Oncology 2011; 22(7):1628-1635.
11. Ioannou MG, Stathakis E, Lazaris AC, et al. Immunohistochemical
evaluation of 95 bone marrow reactive plasmacytoses. Pathol Oncol Res.
2009; 15(1):25-29.
12. Gundesen MT, Lund T, Moeller HEH et al. Plasma Cell Leukemia:
Definition, Presentation, and Treatment.Current oncology reports 2019;
21(8).
13. Musto P, Simeon V, Martorelli MC, et al. Lenalidomide and low-dose
dexamethasone for newly diagnosed primary plasma cell leukemia.
Leukemia. 2014; 28(1):222–225.
14. Royer B, Minvielle S, Diouf M et al. Bortezomib, doxorubicin,
cyclophosphamide, dexamethasone induction followed by stem cell
transplantation for primary plasma cell leukemia: a prospective phase
II study of the Intergroupe Francophone du Myélome. J Clin Oncol.
2016;34:2125–2132.
15. Gavriatopoulou M, Musto P, Caers J et al. European myeloma network
recommendations on diagnosis and management of patients with rare
plasma cell dyscrasias. Leukemia 2018; 32:1883-1898.
16. Drake MB, Lacobelli S, van Biezen A, et al. Primary plasma cell leukemia
and autologous stem cell transplantation. Haemotologica 2010; 95(5):804-
809.
AUGNSKOÐUN | AUGNLÆKNINGAR | LASERAÐGERÐIR | AUGNSTEINASKIPTI
GLÆSIBÆR – ÁLFHEIMAR 74 – 5. HÆÐ - 104 REYKJAVÍK sjonlag.is
ÞAÐ ER EINFALDARA EN
ÞIG GRUNAR AÐ LOSNA
VIÐ GLERAUGUN.
Vissir þú?
s. 577 1001
sjonlag.is eða
heilsuvera.is
PANTAÐU TÍMA
Í FORSKOÐUN
SJÁÐU BETUR